<?xml version="1.0" encoding="UTF-8"?>
<p>RDV is the monophosphoramidate prodrug of C-adenosine nucleoside analogue GS-441524 (1′-cyano 4-aza-7,9-dideazaadenosine C-nucleoside—a compound that is prescribed as therapy against infectious peritonitis in cats and felines, a disease determined by a feline coronavirus) [
 <xref rid="B59-jcm-09-02084" ref-type="bibr">59</xref>,
 <xref rid="B60-jcm-09-02084" ref-type="bibr">60</xref>]. This drug was developed by Gilead Sciences, Inc. as an antiviral candidate against the Ebola virus, but it also proved to be highly efficient in vitro against multiple RNA viruses, both negative sense, paramyxoviridae (parainfluenza type 3 virus, measles and mumps viruses, and nipah virus, among others) and pneumoviridae (respiratory syncytial virus), and positive sense viruses, coronaviridae (SARS-CoV, MERS-CoV, mouse hepatitis virus (MHV), and HCoV-OC43, among others) [
 <xref rid="B60-jcm-09-02084" ref-type="bibr">60</xref>,
 <xref rid="B61-jcm-09-02084" ref-type="bibr">61</xref>,
 <xref rid="B62-jcm-09-02084" ref-type="bibr">62</xref>].
</p>
